(24/7 MARKET NEWS) – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced, this morning, that the FDA cleared the Company’s Investigational New Drug (IND) application, enabling Creative Medical to proceed with initiating a clinical trial for Type 1 Diabetes using AlloStem(TM).
Creative Medical gapped up to open $0.48 and is at $0.4861, up $0.0856 (+21.39%), on volume of 142,519 shares, following a very active premarket session.
Its 52-week range is $0.33 to $9.00, with key inflection points being $0.56, $0.67 and $0.78.
View original content: https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-announces-fda-clearance-of-investigational-new-drug-ind-application-for-allostem-a-novel-cell-therapy-for-the-treatment-of-type-1-diabetes-301667104.htm l
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.